Portage BiotechNASDAQ: PRTG

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

Portage Biotech is in the Healthcare sector

Portage Biotech is in the Biotechnology industry

Portage Biotech is headquartered in British Virgin Islands

Portage Biotech initial public offering (IPO) was on 02 January 2002

https://www.portagebiotech.com

No, Portage Biotech is not included in the S&P 500 index

No, Portage Biotech is not included in the NASDAQ 100 index

No, Portage Biotech is not included in the Dow Jones index